Many management strategies exist for neuroendocrine liver metastases. These strategies range from surgery to ablation with various interventional radiology procedures, and include both regional and systemic therapy with diverse biological, cytotoxic, or targeted agents. A paucity of biological, molecular, and genomic information and an absence of data from rigorous trials limit the validity of many publications detailing management. This Review represents the views from an international conference, for which 15 expert working groups prepared evidence-based assessments addressing specific questions, and from which an independent jury derived final recommendations. The aim of the conference was to review the existing approaches to neuroendocrine liver metastases, assess the evidence on which management decisions were based, develop internationally acceptable recommendations for clinical practice (when evidence was available), and make recommendations for clinical and research endeavours. This report represents the final clinical statements and proposals for future research.

doi.org/10.1016/S1470-2045(13)70362-0, hdl.handle.net/1765/58069
The Lancet Oncology
Department of Nuclear Medicine

Frilling, A., Modlin, I., Kidd, M., Russell, C., Breitenstein, S., Salem, R., … Schilsky, R. (2014). Recommendations for management of patients with neuroendocrine liver metastases. The Lancet Oncology (Vol. 15). doi:10.1016/S1470-2045(13)70362-0